MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?

Pharmacology, Biochemistry, and Behavior
Joshua D VardiganJason M Uslaner

Abstract

Currently prescribed antipsychotics attenuate the positive symptoms of schizophrenia but fail or only mildly improve negative symptoms. The present study aimed to establish an animal model of negative symptoms by examining the effects of the NMDA receptor antagonist MK-801 on sucrose preference. We sought to validate the model by examining the effects of clozapine and D-serine, for which there are positive clinical data regarding their effects on negative symptoms, and haloperidol which is clinically ineffective. We extended our analysis by examining CDPPB, an mGlu5 receptor positive allosteric modulator. Acute MK-801 produced effects indicative of a shift in the hedonic experience of sucrose not confounded by disruptions in motor abilities or taste as revealed by: 1) a decrease in sucrose intake at low concentrations (0.8% or 1.2%), but no effect on water, 2) an increase in consumption for higher (7%) sucrose concentrations, reflecting a shift to the right in the concentration-consumption curve, and 3) no effect on quinine intake. Sub-chronic clozapine and acute d-serine attenuated the MK-801-induced deficit in 1.2% sucrose consumption, whereas sub-chronic haloperidol (0.02 mg/kg) did not. Finally, acute treatment with CDPPB a...Continue Reading

References

Nov 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·P SeemanK Wong
Jan 1, 1990·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·M W OliverG Lynch
Jan 1, 1990·Psychiatry Research·B Kirkpatrick, R W Buchanan
Jan 1, 1987·Psychopharmacology·A TowellP Willner
Feb 1, 1995·Journal of Clinical Psychopharmacology·R L Borison
Nov 15, 1994·European Journal of Pharmacology·S H ZornD R Liston
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Dec 1, 1996·Acta Psychiatrica Scandinavica·G LoasP Boyer
Mar 5, 1997·European Journal of Pharmacology·X P ZengE Richelson
Feb 10, 1998·European Journal of Pharmacology·H RollemaS H Zorn
Oct 27, 1998·Stress : the International Journal on the Biology of Stress·D Marona-Lewicka, D E Nichols
Dec 4, 1998·Biological Psychiatry·G TsaiJ T Coyle
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, R H Roth
Aug 10, 1999·European Journal of Pharmacology·P MichalS Tucek
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·J P MothetS H Snyder
Sep 18, 2001·Current Psychiatry Reports·D C Javitt
Aug 23, 2002·Behavioural Brain Research·Tsuyoshi ShimuraTakashi Yamamoto
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shitij KapurJose N Nobrega
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cecile Spielewoy, Athina Markou
Nov 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yunlei YangShumin Duan
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Oct 14, 2005·Schizophrenia Bulletin·Philip D HarveyChristopher R Bowie
Apr 8, 2006·European Journal of Pharmacology·Feng LiuTerrance H Andree
Oct 2, 2007·Pharmacology, Biochemistry, and Behavior·John-Paul BairdVirginia Hulick

❮ Previous
Next ❯

Citations

Aug 15, 2013·Cell and Tissue Research·Vincenzo MicaleAlexandra Sulcova
Mar 4, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Richard M Cleva, M Foster Olive
Mar 30, 2011·Pharmacology, Biochemistry, and Behavior·Jhodie R Duncan, Andrew J Lawrence
Nov 3, 2010·Neuropharmacology·F NicolettiJ P Pin
Aug 7, 2010·Physiology & Behavior·Danielle Gulick, Alan I Green
Mar 15, 2016·Frontiers in Cellular Neuroscience·Juliana S CassoliDaniel Martins-de-Souza
Apr 12, 2015·Neurochemistry International·Joanna M WierońskaAndrzej Pilc
Oct 1, 2013·Neurobiology of Disease·Hilary Highfield Nickols, P Jeffrey Conn
Dec 3, 2014·Current Opinion in Pharmacology·Adam G Walker, P Jeffrey Conn
Dec 21, 2012·Neuroscience and Biobehavioral Reviews·Natalie Matosin, Kelly A Newell
May 31, 2011·Neuropharmacology·Paige N Vinson, P Jeffrey Conn
Feb 8, 2011·Neuropharmacology·Viviane LabrieJohn C Roder
Nov 30, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Joanna C NeillDominic M Dwyer
Jun 7, 2017·Schizophrenia Bulletin·Samuel A BarnesJared W Young
Feb 1, 2011·Therapeutic Advances in Psychopharmacology·James M Stone
Aug 16, 2019·Psychopharmacology·Adriana Galistu, Paolo S D'Aquila
Apr 28, 2017·Molecular Brain·James MaksymetzP Jeffrey Conn
Oct 27, 2020·Frontiers in Psychiatry·Veronika LangovaJiri Horacek
May 1, 2021·Journal of Clinical Medicine·Waldemar Kryszkowski, Tomasz Boczek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here